AKT1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARAF is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].

ATM is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATM status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATR status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ATRX is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATRX status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BARD1 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 9 clinical trials for endometrial carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA1 status and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [3].

BRCA2 is an inclusion eligibility criterion in 9 clinical trials for endometrial carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA2 status and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [3].

BRIP1 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain BRIP1 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

C11orf30 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain C11orf30 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDK12 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK1 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERBB2 is an inclusion eligibility criterion in 10 clinical trials for endometrial carcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERBB2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC5 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERCC6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCA status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCB status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCC status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCD2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCE status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCF status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCG status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCI status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCL status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCM status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FGF1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF10 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF11 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF12 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF13 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF14 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF16 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF17 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF18 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF20 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF21 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF22 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF23 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF3 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF5 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF6 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF7 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF8 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HDAC1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HDAC2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 5 clinical trials for endometrial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCL1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCL1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MCPH1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MLH1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MRE11A status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MUTYH status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NPM1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PARP1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PARP2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 5 clinical trials for endometrial carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PIK3CA status and endometrial carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PMS2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 7 clinical trials for endometrial carcinoma, of which 7 are open and 0 are closed. Of the trials that contain POLE status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].

PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R1A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R2A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 8 clinical trials for endometrial carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PTEN status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].

RAD50 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD50 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51B status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51C status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51D status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD54L status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain SLX4 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STAG2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

STK11 is an inclusion eligibility criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain STK11 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and endometrial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain XRCC1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].